Disruptive Pharma AB

Disruptive Pharma is an innovative clinical stage biotech and drug delivery company leveraging innovative its mesoporous magnesium carbonate (MMC) technology to enable amorphous drug formulations. Our cutting-edge MMC technology enables the transformation of pharmaceutical assets — APIs, NCEs, or development opportunities — into differentiated, commercially attractive drug products. With the recent advancement of our first product candidate into the clinical stage, we are now entering the scale-up phase, further demonstrating the potential of MMC in real-world drug development. The MMC technology produces stable amorphous formulations with optimal drug product characteristics, making it attractive solution for differentiation, for enablement of novel drugs and in lifecycle management strategies. An MMC amorphous drug simplifies development and optimizes product characteristics. Disruptive Pharma are seeking corporate relationships with biotech and pharmaceutical companies to create additional value across our product portfolio, pre-clinical candidates and MMC technology offerings.